Hosted By:
- Shanghai Institute for Food & Drug Safety
- Sidley Austin LLP
Supported By:
- Shanghai Municipal Food and Drug Administration
Share Insider Analysis from Eminent Speakers on
- Post-Market Drug Safety Systems
- Post-Market Adverse Drug Reaction (ADR) Monitoring
- Means to Ensure Drug Safety Compliance
- Unique Opportunity to Participate in the Process of Revising the China Drug Safety Regulation
Drug Safety is a major international concern, with wide public health implications. In view of the fact, the “Eleventh Five-Year Plan” of the People’s Republic of China includes as a priority food and drug safety, it is a priority to share information and to initiate studies relating to, such experiences overseas.
In order to obtain the experience and input from experts on drug safety both in China and abroad, and to promote the development of drug safety technology and laws, the Shanghai Institute for Food & Drug Safety is initiating an annual series of international conferences. The first one will be the “2008 Drug Safety and Public Policy International Conference: Post-Market Drug Safety” held on October 29-30, 2008, in Shanghai, China.
The Conference will gather an unparalleled ensemble of government officials, experts and lawyers from China and overseas, who will participate in two days of in-depth discussions on drug safety. The working languages of the forum will be English and Chinese. Simultaneous interpretation will be supplied.
This conference will be highly beneficial to the following industries/individuals:
- Pharmaceutical or Biotech Companies
- General Counsel or Legal Counsel
- Regulatory Affairs
- Drug Safety Department
- International Business Development
- Other Managerial Positions
- Food and Drug Administrative Agencies
- Drug Evaluation and ADR Monitoring Agencies
- Research Institutions
- Universities
- Insurance Companies
- Fund Management Organizations
Prominent Speakers from:
- P.R.C. State Food & Drug Administration (SFDA)
- National Center for ADR Monitoring
- Shanghai Food & Drug Administration
- Shanghai Center for ADR Monitoring
- Shanghai Institute for Food & Drug Control
- European Agency for the Evaluation of Medicinal Products (EMEA)
- U.S. Department of Health & Human Service (HHS)
- U.S. District Court (Southern District of New York)
- Bristol-Meyers Squibb
- GE Healthcare
- GlaxoSmithKline
- Johnson & Johnson
- Roche
- sanofi-aventis
- Sidley Austin LLP
- World Class International